Daily Stock Analysis, AVXL, Anavex Life Sciences Corp, priceseries

Anavex Life Sciences Corp. Daily Stock Analysis
Stock Information
Open
3.22
Close
3.15
High
3.23
Low
3.06
Previous Close
3.21
Daily Price Gain
-0.06
YTD High
6.64
YTD High Date
Feb 15, 2017
YTD Low
3.01
YTD Low Date
Dec 11, 2017
YTD Price Change
-0.96
YTD Gain
-23.36%
52 Week High
6.64
52 Week High Date
Feb 15, 2017
52 Week Low
3.01
52 Week Low Date
Dec 11, 2017
52 Week Price Change
-0.93
52 Week Gain
-22.79%
Company Information
Stock Symbol
AVXL
Exchange
NasdaqCM
Company URL
http://www.anavex.com
Company Phone
800-689-3939
CEO
Christopher U. Missling
Headquarters
New York
Business Address
51 W 52ND STREET,, 7TH FLOOR, NEW YORK, NY 10019-6163
Sector
-
Industry Category
Drugs
Industry Group
Biotechnology
CIK
0001314052
About

Anavex Life Sciences Corp. engages in the development of differentiated therapeutics for the treatment of neurodegenerative and neurodevelopmental diseases. It's lead compound, ANAVEXTM 2-73, is being developed to treat Alzheimer's disease, Parkinson's disease, and other central nervous system diseases, including rare diseases, such as Rett syndrome. The company was founded by Harvey Lalach and Athanasios Skarpelos on January 23, 2004 and is headquartered in New York, NY.

Description

Anavex Life Sciences Corp., a clinical stage biopharmaceutical company, engages in the development of drug candidates for the treatment of Alzheimer's disease, other central nervous system diseases, pain, and various cancers. The company's lead drug candidates include ANAVEX 2-73, a Phase 2a clinical trial for the treatment of Alzheimer's disease; and preclinical stage to treat Parkinson's disease. Its preclinical drug candidates include ANAVEX 3-71, which uses ligands that activate sigma-1 and M1 muscarinic receptors to treat Alzheimer's disease; ANAVEX 1-41, a sigma-1 agonist that protects nerve cells from degeneration or death; ANAVEX 1037 for the treatment of prostate cancer; and ANAVEX 1066, a mixed sigma-1/sigma-2 ligand for the treatment of neuropathic and visceral pain. The company was founded in 2006 and is based in New York, New York.